Theialife Sciences Information

Theialife is an innovative early-stage biopharmaceutical company focused on the discovery and development of a first-in-class drug targeting Myopia (near-sightedness). The rising prevalence of Myopia in recent decades, especially in young children has reached an epidemic level across the world. Theialife is committed to developing innovative therapies that address unmet needs in Myopia management.  Our novel Myopia control molecule is a first-in-class oral therapy for the treatment and management of Myopia progression in children. We have completed (a) preclinical development, (b) Phase 2 clinical trial in Denmark, and are in the process of initiating a Global Phase 3 clinical study. Our Product has been used clinically to prevent Myopia progression in more than 1100 Children over the last 12 years in Denmark. All IP related to The Dosage Form and related data is owned by Theialife. This first in class molecule will change the landscape of Myopia management, especially for children who otherwise, given the limited therapies available, are bound to progress towards high myopia, which is a threat to eye-sight.